Lyme vaccine trial shows over 70% efficacy, doctors say

A phase 3 randomized trial of a Lyme vaccine with 9,400 participants reported at least 73% efficacy, and Pfizer and Valneva say they plan to seek federal approval.

A phase 3 randomized clinical trial of a Lyme disease vaccine enrolled 9,400 participants aged 5 and older and reported at least 73 percent efficacy. Doctors involved in reporting the results described the findings as encouraging and said the vaccine appears well tolerated and safe. Stony Brook University Hospital took part in earlier phases of the trial. The companies behind the vaccine, Pfizer and Valneva, announced plans to pursue federal approval. Key facts: - The trial was a phase 3 randomized study involving 9,400 participants aged 5 and up and reported at least 73% efficacy. - Medical professionals described the results as encouraging and reported the vaccine appears well tolerated. - Stony Brook University Hospital participated in early trial phases. - Pfizer and Valneva plan to seek federal approval for the vaccine. Summary: The trial results represent a potential step toward an available human Lyme vaccine, noting that no Lyme vaccine for people is currently available. The next procedural step reported by the companies is a plan to seek federal approval.